Nimotuzumab: Phase II ongoing
YM BioSciences disclosed in its fiscal 2Q11 earnings that it is evaluating whether to continue a pair of double-blind, placebo-controlled, international Phase II trials of nimotuzumab due to lagging recruitment targets. YM declined to disclose the current enrollment in the trials or its timeline for a decision on the trials. The biotech said it would instead focus on advanced trials involving partner Daiichi Sankyo, including a planned pivotal trial of nimotuzumab in gastric cancer. One trial is evaluating nimotuzumab plus radiotherapy in 128 patients for the palliative treatment of NSCLC and the second trial is evaluating radiotherapy with and without 200 mg of IV nimotuzumab given weekly in 88 patients with brain metastases from NSCLC. ...